EichorEICHOR
Location: Lake Worth Synced from ClinicalTrials.gov · August 09, 2026

Clinical studies recruiting near Lake Worth

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart
Phase 3 · Colorado Prevention Center · NCT06024746A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain
Phase 2 · Eli Lilly and Company · NCT05986292Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Phase 2/Phase 3 · NRG Oncology · NCT05174169A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H
Phase 2/Phase 3 · AbbVie · NCT06345339Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carci
Phase 3 · National Cancer Institute (NCI) · NCT05256225SELUTION 4 De Novo Small Vessel IDE Trial
NA · M.A. Med Alliance S.A. · NCT05946629Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescent
Phase 2 · National Cancer Institute (NCI) · NCT06900595Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Inva
Phase 2 · National Cancer Institute (NCI) · NCT07061964Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectab
Phase 2 · NRG Oncology · NCT05327686A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psori
Phase 4 · Eli Lilly and Company · NCT06864026mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Neg
Phase 3 · Alliance for Clinical Trials in Oncology · NCT05677490A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic Pain
Phase 2 · Eli Lilly and Company · NCT07285018A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
Phase 3 · Eli Lilly and Company · NCT07282600Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Remo
Phase 2/Phase 3 · National Cancer Institute (NCI) · NCT05987241Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Phase 3 · ECOG-ACRIN Cancer Research Group · NCT04423211S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac
Phase 3 · SWOG Cancer Research Network · NCT03418961Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer
Phase 4 · Pfizer · NCT06952660Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabo
Phase 2 · National Cancer Institute (NCI) · NCT03866382Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung
Phase 3 · National Cancer Institute (NCI) · NCT04267848A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participant
Phase 3 · AbbVie · NCT05889182Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Phase 3 · ECOG-ACRIN Cancer Research Group · NCT03937635Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Phase 2/Phase 3 · SWOG Cancer Research Network · NCT03851445Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance C
Phase 3 · National Cancer Institute (NCI) · NCT07061977Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Phase 3 · NRG Oncology · NCT06580314Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
Phase 2 · National Cancer Institute (NCI) · NCT05112601Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Phase 3 · National Cancer Institute (NCI) · NCT04181060Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After
Phase 3 · Alliance for Clinical Trials in Oncology · NCT05812807A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirv
Phase 2 · AbbVie · NCT07059845MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
Phase N/A · Lake Worth Surgical Center · Stryker Instruments · NCT03072927A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
Phase 3 · Hoffmann-La Roche · NCT07170150
Look up another city
Look up another condition
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.